Melanoma has emerged as the paradigm tumor for drug development through mutation-targeted therapies (inhibitors targeting BRAF, MEK, and c-KIT) and immunotherapy. Exploring the combinations of both approaches is a challenge that will require scientific rationale and the cooperation of the pharmaceutical industry. But, with these challenges comes another opportunity to change the paradigms in drug development.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma
Journal of Hematology & Oncology Open Access 04 March 2019
-
Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts
Journal of Experimental & Clinical Cancer Research Open Access 16 November 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).
Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
Infante, J. R. et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) [abstract]. J. Clin. Oncol. 29 (Suppl.), CRA8503J (2011).
Carvajal, R. D. et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 305, 2327–2334 (2011).
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).
Hoos, A. et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102, 1388–1397 (2010).
Green, D. R., Ferguson, T., Zitvogel, L. & Kroemer, G. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9, 353–363 (2009).
Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167–3175 (2010).
Eggermont, A. M. et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur. J. Cancer. doi:10.1016/j.ejca.2011.09.028
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare they are consultants for Bristol-Myers Squibb, Glaxo-Smithkline, Merck and Roche and receive research honoraria from Merck.
Rights and permissions
About this article
Cite this article
Eggermont, A., Robert, C. A new paradigm tumor for drug development. Nat Rev Clin Oncol 9, 74–76 (2012). https://doi.org/10.1038/nrclinonc.2011.201
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.201
This article is cited by
-
Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma
Journal of Hematology & Oncology (2019)
-
Regulatory T cells in the immunotherapy of melanoma
Tumor Biology (2016)
-
Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts
Journal of Experimental & Clinical Cancer Research (2013)
-
HLA-A*0201 + Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients
Journal of Investigative Dermatology (2012)